LAG3 and neoplasm: Lymphocyte activation gene-3 (LAG-3) is a T cells-associated inhibitor receptor that co-expressed with PD-1 on anergic or exhaustion T cells.632 Preclinical studies have shown that LAG-3 and PD-1 blockades synergistically stimulate T cell responses and decrease tumor burden in murine model.633–635 There are two LAG-3 inhibitors in clinical trials, IMP-321 and relatlimab (BMS-986016).